Fenticonazole nitrate (FTN) is a potent antifungal drug adopted in the treatment of vaginal candidiasis. It has inadequate aqueous solubility hence, novel ultra-deformable liposomes 'Terpesomes' (TPs) were developed that might prevail over FTN poor solubility besides TPs might abstain the obstacles of mucus invasion. TPs were assembled by thin-film hydration then optimized by Box Behnken design utilizing terpenes ratio (X), sodium deoxycholate amount (X), and ethanol concentration (X) as independent variable, whereas their impact was inspected for entrapment efficiency (Y), particle size (Y), and polydispersity index (Y). Design Expert was bestowed to select the optimal TP for more studies. The optimal TP had entrapment efficiency of 62.18 ± 1.39%, particle size of 310.00 ± 8.16 nm, polydispersity index of 0.20 ± 0.10, and zeta potential of -10.19 ± 0.2.00 mV. Elasticity results were greater in the optimal TP related to classical bilosomes. Further, permeation illustrated tremendous permeability from the optimal TP correlated to classical bilosomes, and FTN suspension. Besides, assessment displayed significant inhibition effect in rats from FTN-TPs gel compared to FTN gel. The antifungal potency with undermost histopathological variation was detected in rats treated with FTN-TPs gel. Overall, the acquired findings verified the potency of utilizing FTN-TPs gel for treatment of vaginal candidiasis.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7594706 | PMC |
http://dx.doi.org/10.1080/10717544.2020.1837295 | DOI Listing |
Urogynecology (Phila)
December 2024
From the Albany Medical Center Department of Obstetrics and Gynecology, Division of Urogynecology, Albany, NY.
Importance: A vaginal pessary is a highly effective treatment for patients with pelvic organ prolapse (POP). Patient views of pessaries and how their beliefs affect whether they choose pessary treatment is unknown.
Objective: Our objective of this study was to describe the knowledge, understanding, and patient concerns regarding pessary use for POP management.
BMC Pregnancy Childbirth
January 2025
Department of Obstetrics and Gynaecology, Adesh Institute of Medical Sciences and Research, Bathinda, Punjab, 151001, India.
Background: Placenta accreta spectrum (PAS) disorder is a fatal condition responsible for obstetric haemorrhage, which contributes to increased feto-maternal morbidity and mortality. The main contributing factor is a scarred uterus, often from a previous cesarean delivery, myomectomy, or uterine instrumentation. The occurrence of PAS in an unscarred uterus is extremely rare, with only anecdotal cases reported so far in the literature.
View Article and Find Full Text PDFInflamm Bowel Dis
January 2025
Division of Gastroenterology, University of California, San Francisco, San Francisco, CA, USA.
Background: Women with inflammatory bowel disease (IBD) face complexities of disease management during pregnancy and childbirth. Apprehension regarding vaginal delivery in pregnant individuals with IBD persists due to concern for perianal disease and perineal trauma. The incidence of poor wound healing after obstetric anal sphincter injury is approximately 4% in the general population.
View Article and Find Full Text PDFJ Sex Med
January 2025
Department of Urology, Hospital Universitario 12 de Octubre-imas12, Madrid, 28040, Spain.
Background: Urinary tract infections (UTIs) significantly impact quality of life and can also lead to changes in sexual function.
Aim: This study aims to assess the symptoms associated with recurrent urinary tract infections (rUTIs) and their influence on both quality of life and sexual activity.
Methods: A case-control study was conducted, involving 383 patients with rUTIs and 161 healthy controls.
AIDS Res Hum Retroviruses
January 2025
Servicio de Ginecología y Obstetricia, Hospital Universitario Torrecárdenas, GAEPI-VPH (Grupo Andaluz para el Estudio y la Prevención de la Infección por VPH), Almería, Spain.
Infection with Human immunodeficiency virus (HIV) shows a higher risk of infection by Human papillomavirus (HPV). We aim to provide evidence about the effect of a -based vaginal gel (Papilocare®) for treating HPV in women with HIV. Women ≥25 years coinfected by endocervical HPV and with low-grade abnormal cervicovaginal cytology were treated for 6 months with Papilocare® in this observational, prospective, non-controlled pilot study.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!